Michael J. Brubaker, PhD

Michael J. Brubaker, PhD

Chief Scientific Officer

Dr. Brubaker is a recognized pharmaceutical drug and medical device development expert with 25 years of experience with an emphasis in the ophthalmology, otic and respiratory disease areas. Prior to joining Xequel, Dr. Brubaker worked at Novartis Pharmaceutical Corp. as a Global Program Head in the Ophthalmology Development Unit responsible for setting the ophthalmic digital Software as a Medical Device (SaMD) development strategy and leading the Xiidra® & Ophtha Digital global program teams. Previously, he worked at Abbott Laboratories, Bausch & Lomb Pharmaceuticals, and Alcon Laboratories, where he held various positions of increasing responsibility within clinical research, project strategic leadership, and as the VP of enterprise-wide project/program management in various ophthalmology disease areas. Dr. Brubaker earned his B.S. and M.S. degrees in Chemistry and a Ph.D. in Bio-organic Chemistry from Wichita State University, and he was a post- doctoral fellow at the University of California, Berkeley, Department of Molecular and Cell Biology.